BioMarin Pharma, Amgen, Sarepta Therapeutics, Chelsea Therapeutics Intl., and Theravance Early Briefing and Review PR Newswire LONDON, March 7, 2013 LONDON, March 7, 2013 /PRNewswire/ -- Markets inched up higher yesterday after hitting all time highs earlier this week. The healthcare sector also showed promise as the the sector's stocks moved up. The Dow Jones ended its latest session at 14,296.24, up 0.30 percent while NASDAQ was down 0.05 percent to close at 3,222.37. Conversely, S&P also ended on a positive note at 1,541.46, up 0.11 percent. Our research team took a look at the biotech industry including major companies like BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Amgen Inc. (NASDAQ: AMGN), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Chelsea Therapeutics International Ltd (NASDAQ: CHTP) and Theravance Inc. (NASDAQ: THRX). StockCall has released free charting and technical research on these aforementioned companies. Register to read these reports at http://www.stockcall.com/report BioMarin Pharmaceutical Inc. traded in the range of $60.30 and $61.64 in its latest trading session and ended the day at $61.25, up 1.02 percent. The stock's 52 weeks range stands at $31.91 and $61.64. BioMarin Pharma has gained 73.07 percent of its value in the past 12 months, while it gained 24.49 percent so far in 2013. The biotech company is in a bullish mode and may find its first support level at $59.30. It is trading above its 20-day moving average of $56.48. Sign up for the free report on BMRN at http://www.StockCall.com/BMRN030713.pdf Shares of Amgen Inc. ended yesterday's trading session marginally down at $93.27 that is a drop of 0.18 percent, after creating a new 52 weeks high. The stock gained more than 8 percent this year, in-line with the broad market. The stock has slipped from $94.29 resistance level, which is also its new 52-week high. It has support at around $92.36 at the moment. Despite its downward move, Amgen is still trading above its 6-day and 20-day moving averages. AMGN free technical report can be accessed by signing up at http://www.StockCall.com/AMGN030713.pdf With a sharp upward movement in Wednesday's trading session, Sarepta Therapeutics Inc. is up 21.36 percent for the year. It has gained 2,969 percent in the past 52 weeks. The stock closed 2.89 percent up at $31.31 on volume of 1.73 million shares. Its average trading volume stands at 1.34 million shares. The company's shares currently face resistance at around $31.52. The stock has support at around $28.14. It is currently trading above its 20-day and 50-day moving averages, which is a bullish signal. Free report on SRPT can be accessed by registering at http://www.StockCall.com/SRPT 030713.pdf Chelsea Therapeutics International Ltd traded in the range of $1.68 and $1.79 during yesterday's trading session. It opened at $1.69 and closed at $1.77, up 2.91 percent. The stock is currently in a bullish mode and has its first resistance level at $1.87. Upon breaching this level, the biotech company may go as high as $1.87. It traded 976,000 shares and is in-line with its 50-day moving average price. Its first support level is at $1.48. In 2013, the stock is up 132.89 percent so far. Register with StockCall and download the research on CHTP for free at http://www.StockCall.com/CHTX030713.pdf Despite the upward move shown by broad market indices, Theravance Inc.'s stock finished 1.62 percent lower at $24.29, with volume down from daily average of 1.25 million to 944,000. The company's stock is up in 2013 so far with its year-to-date gain at 9.22 percent. However, the stock currently shows a neutral trend which is further confirmed by the stock's MACD chart. Theravance has its first support level at $23.48. Read the full free research on THRX by signing up to StockCall at http://www.StockCall.com/THRX030713.pdf About StockCall.com StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at http://www.stockcall.com SOURCE StockCall.com Contact: Contact Person:William T. Knight, Email: firstname.lastname@example.org, Contact Number: +1(646)396-9857 (9:00 am EST - 01:30 pm EST)
BioMarin Pharma, Amgen, Sarepta Therapeutics, Chelsea Therapeutics Intl., and Theravance Early Briefing and Review
Press spacebar to pause and continue. Press esc to stop.